LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

2,564
Mkt Cap
$4.06B
Volume
234,918.00
52W High
$212.49
52W Low
$93.58
PE Ratio
99.18
LGND Fundamentals
Price
$199.03
Prev Close
$206.05
Open
$209.13
50D MA
$184.31
Beta
0.97
Avg. Volume
141,175.57
EPS (Annual)
-$0.2204
P/B
4.26
Rev/Employee
$2.46M
Loading...
Loading...
News
all
press releases
Ligand Pharmaceuticals Incorporated $LGND Position Decreased by Calamos Advisors LLC
Calamos Advisors LLC reduced its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 38.7% during the second quarter, according to its most recent filing with the...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Impax Asset Management Group plc
Impax Asset Management Group plc trimmed its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 7.1% in the second quarter, according to the company in its most...
MarketBeat·6d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High - What's Next...
MarketBeat·7d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says
Benchmark lifted their price objective on shares of Ligand Pharmaceuticals from $175.00 to $220.00 and gave the company a "buy" rating in a report on Friday...
MarketBeat·12d ago
News Placeholder
HC Wainwright Increases Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $231.00
HC Wainwright lifted their target price on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the company a "buy" rating in a report on Thursday...
MarketBeat·13d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High Following Earnings Beat
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High Following Earnings Beat...
MarketBeat·13d ago
News Placeholder
Cornerstone Investment Partners LLC Takes Position in Ligand Pharmaceuticals Incorporated $LGND
Cornerstone Investment Partners LLC bought a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 2nd quarter, according to the company in its most recent disclosure...
MarketBeat·13d ago
News Placeholder
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Moderate Buy" by Brokerages
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are currently covering the stock, Marketbeat...
MarketBeat·14d ago
News Placeholder
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director John Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, November 3rd. The...
MarketBeat·14d ago
News Placeholder
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Stocktwits·4mo ago

Latest LGND News

View

Advertisement|Remove ads.

Advertisement|Remove ads.